Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    December 2018
  1. HANAUER SB
    Targeting Crohn's disease.
    Lancet. 2018;390:2742-2744.
    PubMed     Text format    


  2. COLOMBEL JF, Panaccione R, Bossuyt P, Lukas M, et al
    Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Lancet. 2018;390:2779-2789.
    PubMed     Text format     Abstract available


    April 2018
  3. COLOMBEL JF, Panaccione R, Petersson J, Robinson AM, et al
    Clinical disease activity in the CALM study - Authors' reply.
    Lancet. 2018;391:1482.
    PubMed     Text format    


  4. HERFARTH H, Long MD, Isaacs KL
    Clinical disease activity in the CALM study.
    Lancet. 2018;391:1481-1482.
    PubMed     Text format    


    October 2017
  5. KAMM MA
    Rapid changes in epidemiology of inflammatory bowel disease.
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32669.
    PubMed     Text format    


  6. NG SC, Shi HY, Hamidi N, Underwood FE, et al
    Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32448.
    PubMed     Text format     Abstract available


    July 2017
  7. DE JONG MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, et al
    Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.
    Lancet. 2017 Jul 14. pii: S0140-6736(17)31327.
    PubMed     Text format     Abstract available


    June 2017
  8. VESELY R, Richardson P
    The switch to infliximab biosimilars.
    Lancet. 2017;389:2266-2268.
    PubMed     Text format    


    May 2017
  9. LAHARIE D
    Towards therapeutic choices in ulcerative colitis.
    Lancet. 2017 May 17. pii: S0140-6736(17)31263.
    PubMed     Text format    


  10. VERMEIRE S, Sandborn WJ, Danese S, Hebuterne X, et al
    Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 May 17. pii: S0140-6736(17)30930.
    PubMed     Text format     Abstract available


  11. JORGENSEN KK, Olsen IC, Goll GL, Lorentzen M, et al
    Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Lancet. 2017 May 11. pii: S0140-6736(17)30068.
    PubMed     Text format     Abstract available


    February 2017
  12. PARAMSOTHY S, Kamm MA, Kaakoush NO, Walsh AJ, et al
    Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
    Lancet. 2017 Feb 14. pii: S0140-6736(17)30182.
    PubMed     Text format     Abstract available


  13. SIEGMUND B
    Is intensity the solution for FMT in ulcerative colitis?
    Lancet. 2017 Feb 14. pii: S0140-6736(17)30313.
    PubMed     Text format    


    January 2017
  14. THE LANCET
    A cure for Crohn's disease by 2032.
    Lancet. 2017;389:226.
    PubMed     Text format    


  15. ANANTHAKRISHNAN AN
    Filgotinib for Crohn's disease-expanding treatment options.
    Lancet. 2017;389:228-229.
    PubMed     Text format    


  16. VERMEIRE S, Schreiber S, Petryka R, Kuehbacher T, et al
    Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Lancet. 2017;389:266-275.
    PubMed     Text format     Abstract available


    November 2016
  17. UNGARO R, Mehandru S, Allen PB, Peyrin-Biroulet L, et al
    Ulcerative colitis.
    Lancet. 2016 Nov 30. pii: S0140-6736(16)32126.
    PubMed     Text format     Abstract available


    September 2016
  18. CICCOCIOPPO R, Corazza GR
    Mesenchymal stem cells for fistulising Crohn's disease.
    Lancet. 2016;388:1251-2.
    PubMed     Text format    


  19. PANES J, Garcia-Olmo D, Van Assche G, Colombel JF, et al
    Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
    Lancet. 2016;388:1281-90.
    PubMed     Text format     Abstract available


    July 2016
  20. LYNCH RW, Soane T, Gibson R, Pal S, et al
    Bilateral lower limb weakness in acute severe ulcerative colitis.
    Lancet. 2016;388:101-2.
    PubMed     Text format    


  21. STAHEL PF
    The inherent dangers of high-dose steroids for acute inflammatory conditions.
    Lancet. 2016;388:102.
    PubMed     Text format    


    February 2016
  22. KHANNA R
    Immunosuppression for management of Crohn's disease - Author's reply.
    Lancet. 2016;387:748.
    PubMed     Text format    


  23. MILOSEVIC I, Dale A, Drysdale H, Mahtani K, et al
    Immunosuppression for management of Crohn's disease.
    Lancet. 2016;387:747.
    PubMed     Text format    


  24. HERFARTH HH, Long MD, Kappelman MD
    Immunosuppression for management of Crohn's disease.
    Lancet. 2016;387:747-8.
    PubMed     Text format    


    October 2015
  25. CLEYNEN I, Boucher G, Jostins L, Schumm LP, et al
    Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.
    Lancet. 2015 Oct 16. pii: S0140-6736(15)00465.
    PubMed     Text format     Abstract available


  26. TORRES J, Colombel JF
    Genetics and phenotypes in inflammatory bowel disease.
    Lancet. 2015 Oct 16. pii: S0140-6736(15)00464.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: